Announcements

BioNTech SE (NASDAQ: BNTX) Chief Executive Officer Sahin Ugur sold 20,500 shares at $96.31 per share on Sep. 10. Following the transaction, he owned 688,209 shares.

Cellectis S.A. (NASDAQ: CLLS) announced that it will host a business update call and webcast on September 14, 2026. The event will provide a business update through conference-call and webcast formats.

Edwards Lifesciences Corp (NYSE: EW) executive Daniel Lippis exercised options covering 619 shares at $72.68 per share on September 11, 2026. He also sold 619 shares at $87.51 per share on the same date.

Barinthus Biotherapeutics plc. reported a passive-stake amendment tied to a transaction involving 8,797,770 shares at $0.11 per share. Oxford Science Enterprises plc is the named reporting party.

Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) reported £3.23 million in cash and cash equivalents at June 30, 2026, after six months of interim activity and a $3.5 million gross fundraise completed on July 1. The company announced an Early Access Program for eRapa and approval …

The securities are held by selling shareholders, while the company reported gross proceeds of $3.5 million from a fundraise completed on July 1, 2026. The ordinary shares carry a nominal value of £0.000001 per share.

Annovis Bio, Inc. (NYSE: ANVS) will ask shareholders on October 14, 2026, to approve a charter amendment raising authorized common stock from 70,000,000 shares to 140,000,000 shares. The same proposal would increase authorized preferred stock from 2,000,000 shares to 10,000,000 shares. The special meeting …